NASDAQ:ENDP

Endo International - ENDP Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.

Add

Compare

Today's Range: N/A
50-Day Range: $0.28
▼
$0.75
52-Week Range: N/A

Volume: 1.49 million shs
Average Volume: 28.19 million shs
Market Capitalization: $68.19 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $2.50

Endo International MarketRank™ Forecast

Analyst Rating: Hold
1.67 Rating Score
Upside/Downside: ∞ Upside
$2.50 Price Target
Short Interest: Healthy
8.47% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -2.62
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: -83.33%
From $0.78 to $0.13 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.87 out of 5 stars

Medical Sector

830th out of 1,096 stocks

Pharmaceutical Preparations Industry

406th out of 548 stocks

2.8

Analyst's Opinion

Consensus Rating
Endo International has received a consensus rating of Hold. The company's average rating score is 1.67, and is based on 1 buy rating, no hold ratings, and 2 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $2.50, Endo International has a forecasted upside of ∞ from its current price of $0.00.
Amount of Analyst Coverage
Endo International has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
8.47% of the outstanding shares of Endo International have been sold short.
Short Interest Ratio / Days to Cover
Endo International has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Endo International has recently decreased by 45.59%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Endo International does not currently pay a dividend.
Dividend Growth
Endo International does not have a long track record of dividend growth.

3.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Endo International has received a 40.36% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Frovatriptan succinate", "Other cancer medication", "Isosorbide dinitrate", "Oxycodone", "Cyanocobalamin", and "Paracetamol" products. See details.
Environmental Sustainability
The Environmental Impact score for Endo International is -2.62.

1.1

News and Social Media Coverage

News Sentiment
Endo International has a news sentiment score of 0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Endo International this week, compared to 4 articles on an average week.
Search Interest
Only 13 people have searched for ENDP on MarketBeat in the last 30 days. This is a decrease of -87% compared to the previous 30 days.
MarketBeat Follows
Only 28 people have added Endo International to their MarketBeat watchlist in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Endo International insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.20% of the stock of Endo International is held by insiders.
Percentage Held by Institutions
80.39% of the stock of Endo International is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Endo International are expected to decrease by -83.33% in the coming year, from $0.78 to $0.13 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Endo International is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Endo International is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Endo International (NASDAQ:ENDP) Stock

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.

Receive ENDP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Endo International and its competitors with MarketBeat's FREE daily newsletter.

ENDP Stock News Headlines

September 27, 2022 | americanbankingnews.com

Endo International (NASDAQ:ENDP) Now Covered by Analysts at StockNews.com

September 21, 2022 | reuters.com

ENDP.O

September 21, 2022 | americanbankingnews.com

Endo International (NASDAQ:ENDP) Receives New Coverage from Analysts at StockNews.com

September 18, 2022 | seekingalpha.com

ENDPQ Endo International plc

September 9, 2022 | thestreet.com

Endo Int'l (ENDP) Stock Spikes as Biotech Rallies

September 8, 2022 | wsj.com

Firm Retention Summary: Endo International PLC

September 1, 2022 | cnbc.com

Endo International PLC ENDP

August 19, 2022 | seekingalpha.com

Endo: End Game And What Burned Investors Can Learn

August 19, 2022 | finance.yahoo.com

Endo Luxembourg Finance I Company S.a.r.l. -- Moody's downgrades Endo's PDR to D-PD following Chapter 11 filing

August 19, 2022 | benzinga.com

Thinking about buying stock in Endo International, Vistagen Therapeutics, Applied DNA Sciences, Ford Motor, or Mobiquity Technologies?

August 17, 2022 | benzinga.com

Thinking about buying stock in Endo International, T2 Biosystems, SoFi Technologies, Nu Holdings, or Bloom Energy?

August 17, 2022 | finance.yahoo.com

Endo Files For Chapter 11 As US Opioid Litigation Goes On, Reaches $450M Settlement For Opioid Crisis

August 17, 2022 | investorplace.com

What Is Going on With Endo International (ENDP) Stock Today?

August 17, 2022 | finance.yahoo.com

Endo files for bankruptcy as U.S. opioid litigation drags

August 17, 2022 | finance.yahoo.com

Drugmaker Endo Files for Bankrupty Over Debt, US Opioid Litigation

August 17, 2022 | finance.yahoo.com

UPDATE 2-Endo files for bankruptcy as U.S. opioid litigation drags

August 16, 2022 | msn.com

Massachusetts AG reaches settlement with opioid maker Endo

August 16, 2022 | nasdaq.com

Endo Files For Chapter 11 Bankruptcy Protection

August 13, 2022 | coinjournal.net

TUSD Receives Endorsement from Data Analysis Firm CryptoQuant

August 9, 2022 | finance.yahoo.com

Drugmaker Endo Says Bankruptcy Likely Imminent

August 9, 2022 | fool.com

State Pensions, University Endowments Take a Beating in Market Rout

August 9, 2022 | finance.yahoo.com

Endo Shares Plunge On Imminent Bankruptcy Filing

August 9, 2022 | markets.businessinsider.com

ENDO REPORTS SECOND-QUARTER 2022 FINANCIAL RESULTS

August 9, 2022 | nasdaq.com

Endo International Q2 Adj. Profit From Cont. Ops. Declines

August 8, 2022 | finance.yahoo.com

Paladin Labs Announces Health Canada's Filing Acceptance of Cenobamate Tablets as an Adjunctive Therapy for the Management of Partial-Onset Seizures in Adults with Epilepsy

See More Headlines

Receive ENDP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Endo International and its competitors with MarketBeat's FREE daily newsletter.

ENDP Company Calendar

Last Earnings: 11/04/2021
Today: 9/29/2022
Next Earnings (Estimated): 11/03/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Sector: Medical
Current Symbol: NASDAQ:ENDP
CUSIP: 29264F20
CIK: 1593034
Web: www.endo.com
Phone: (531) 268-2000
Fax: 800-329-3636
Employees: 3,103
Year Founded: 1997

Price Target and Rating

Average Stock Price Forecast: $2.50
High Stock Price Forecast: $6.00
Low Stock Price Forecast: $1.00
Consensus Rating: Hold
Rating Score (0-4): 1.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($11.07)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-613,240,000.00
Net Margins: -93.31%
Pretax Margin: -91.14%
Return on Equity: -34.25%
Return on Assets: 6.72%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.86
Quick Ratio: 1.62

Sales & Book Value

Annual Sales: $2.99 billion
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: 0.06
Book Value: ($13.60) per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 235,143,000
Free Float: 232,321,000
Market Cap: $68.19 million
Optionable: Optionable
Beta: 1.15

Social Links

Key Executives

Mr. Blaise A. Coleman (Age 48)
Pres, CEO & Director
Comp: $20.93M

Mr. Mark T. Bradley (Age 52)
Exec. VP & CFO
Comp: $6.27M

Mr. Matthew Joseph Maletta (Age 50)
Exec. VP, Chief Legal Officer & Company Sec.
Comp: $7.02M

Mr. Patrick A. Barry (Age 54)
Exec. VP & Pres of Global Commercial Operations
Comp: $6.15M

Frank B. Raciti
VP, Controller & Chief Accounting Officer

Ms. Cheryl Stouch
Sr. VP of Information Technology & Chief Information Officer

Ms. Laure E. Park
Sr. VP of Investor Relations & Corp. Affairs

Ms. Susan Williamson
Sr. VP & Chief Compliance Officer

Ms. Tracy Basso
Chief HR Officer

Mr. James Papp
Head of Endo Ventures Limited & Sr. VP of Global Supply Chain

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ENDP Stock - Frequently Asked Questions

Should I buy or sell Endo International stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Endo International in the last year. There are currently 2 sell ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ENDP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ENDP, but not buy additional shares or sell existing shares.
View ENDP analyst ratings or view top-rated stocks.
What is Endo International's stock price forecast for 2022?: 3 Wall Street research analysts have issued 1-year target prices for Endo International's stock. Their ENDP share price forecasts range from $1.00 to $6.00. On average, they anticipate the company's share price to reach $2.50 in the next twelve months.
View analysts price targets for ENDP or view top-rated stocks among Wall Street analysts.
When is Endo International's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our ENDP earnings forecast.
How were Endo International's earnings last quarter?: Endo International plc (NASDAQ:ENDP) announced its quarterly earnings data on Thursday, November, 4th. The company reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.34. The firm earned $772.03 million during the quarter, compared to analysts' expectations of $667.94 million. Endo International had a negative net margin of 93.31% and a negative trailing twelve-month return on equity of 34.25%. The firm's revenue was up 21.6% compared to the same quarter last year. During the same quarter last year, the firm earned $0.52 earnings per share.

What is Paul Campanelli's approval rating as Endo International's CEO?: 25 employees have rated Endo International Chief Executive Officer Paul Campanelli on Glassdoor.com. Paul Campanelli has an approval rating of 86% among the company's employees.
What other stocks do shareholders of Endo International own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Endo International investors own include Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Mallinckrodt (MNK), Gilead Sciences (GILD), TherapeuticsMD (TXMD), Micron Technology (MU), Cleveland-Cliffs (CLF), Pfizer (PFE), Advanced Micro Devices (AMD) and NVIDIA (NVDA).
What is Endo International's stock symbol?: Endo International trades on the NASDAQ under the ticker symbol "ENDP."
How much money does Endo International make?: Endo International (NASDAQ:ENDP) has a market capitalization of $0.00 and generates $2.99 billion in revenue each year. The company earns $-613,240,000.00 in net income (profit) each year or ($11.07) on an earnings per share basis.
How many employees does Endo International have?: The company employs 3,103 workers across the globe.
How can I contact Endo International?: Endo International's mailing address is First Floor Minerva House Simmonscourt Road Ballsbridge, Dublin L2, 19355. The official website for the company is www.endo.com. The company can be reached via phone at (531) 268-2000, via email at relations.investor@endo.com, or via fax at 800-329-3636.

This page (NASDAQ:ENDP) was last updated on 9/29/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Endo International - ENDP Stock Forecast, Price & News

Endo International MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Endo International (NASDAQ:ENDP) Stock

ENDP Stock News Headlines

ENDP Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

ENDP Stock - Frequently Asked Questions

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™